经导管直肠动脉化疗栓塞联合奥沙利铂与S-1同步放化疗可提高局部晚期直肠癌病理缓解率
这项前瞻性单中心非随机对照研究纳入95例局部晚期直肠癌患者,比较经导管直肠动脉化疗栓塞(TRACE)联合奥沙利铂与S-1同步放化疗(NATRACE-CRT组,n=50)与标准氟尿嘧啶类同步放化疗(NA-CRT组,n=45)的新辅助治疗效果。主要终点为术后病理退缩率,NATRACE-CRT组TRG0+1率为60%,显著高于NA-CRT组的33.33%(P=0.013),两组毒副反应与手术并发症相似。
要点
- NATRACE-CRT组TRG0+1率为60%,显著高于NA-CRT组的33.33%(P=0.013)。
- 两组TRG0率分别为30%与17.78%(P=0.231),差异无统计学意义。
- 两组术前毒副反应与手术并发症发生率相似。
核心结论
- TRACE联合奥沙利铂与S-1同步放化疗作为新辅助治疗,较标准治疗提供更好的病理缓解率,安全性相似。
研究设计与样本
- 前瞻性、单中心、非随机对照临床研究,共纳入95例局部晚期直肠癌患者,NATRACE-CRT组50例,NA-CRT组45例。
主要发现
- NATRACE-CRT组TRG0为30%(95%CI 16.8-43.2),NA-CRT组为17.78%(95%CI 6.2-29.4),P=0.231。
- NATRACE-CRT组TRG0+1率为60%(95%CI 45.9-74.1),NA-CRT组为33.33%(95%CI 19-47.7),P=0.013。
- NATRACE-CRT组ORR为84%,NA-CRT组为66.67%(P=0.058)。
- 两组术前毒副反应与手术并发症发生率相似。
关键数值与推荐
- 病理退缩率采用AJCC第7版肿瘤退缩分级(TRG)评估。
- 主要终点为术后病理退缩率,次要终点包括客观缓解率(ORR)、毒性、手术并发症及术后肿瘤降期。
临床怎么用
- 对于局部晚期直肠癌新辅助治疗,可考虑TRACE联合奥沙利铂与S-1同步放化疗以争取更高病理缓解,但需注意证据来自非随机单中心研究。
局限性
- 研究为单中心、非随机设计,样本量有限(共95例),结论需进一步随机对照研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To explore the efficacy and safety of Transcatheter rectal arterial chemoembolization with oxaliplatin and S-1 concurrent chemoradiotherapy as neoadjuvant therapy for locally advanced rectal cancer. METHODS: This s a prospective, monocentric, non-randomized clinical study, a total of 95 patients were enrolled and assigned to two groups: an investigational group (n = 50) receiving transcatheter rectal arterial chemoembolization (TRACE) with oxaliplatin and preoperative radiotherapy plus S-1 concurrent chemotherapy (NATRACE-CRT), followed by surgery, a control group (n = 45) receiving standard fluorouracil-based combined modality treatment, consisting of preoperative radiotherapy plus capecitabine based chemotherapy (NA-CRT), followed by surgery. The primary endpoint was postoperative pathological regression rate which evaluated by tumor regression grade (TRG) according to the 7th edition of the American Joint Committee on Cancer (AJCC) standard, and the secondary endpoints included objective response rate (ORR) and toxicity, as well as surgical complications, and postoperative tumor downstaging. RESULTS: Compared with NA-CRT group (17.78% (95% confidence interval (CI): 6.2-29.4)), the TRG0 was 30% (95% CI 16.8-43.2) in the NATRACE-CRT group (P = 0.231). The TRG0 + 1 rate was 60% (95% CI: 45.9-74.1) and 33.33% (95% CI: 19-47.7) in NATRACE-CRT group and NA-CRT group, respectively (P = 0.013). The ORR of the NATRACE-CRT group was 84% and that of the NA-CRT group was 66.67% (p = 0.058). Incidence of preoperative toxic side effects and surgical complications was similar between the two groups. CONCLUSION: TRACE with oxaliplatin plus concurrent S-1 chemoradiotherapy as a neoadjuvant therapy provided better pathological remission rate versus standard treatment with a similar safety profile. TRIAL REGISTRATION: NCT03601156.
引用
- Yang B, Shan J, Feng Y, et al. Transcatheter rectal arterial chemoembolization with oxaliplatin plus S-1 concurrent chemoradiotherapy can improve the pathological remission rate in locally advanced rectal cancer: a comparative study. Radiat Oncol. 2020. PMID: 32375814. doi:10.1186/s13014-020-01540-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。